CD274 and small cell lung carcinoma: In small cell lung cancer (SCLC) patients, the incidence of immune‐related adverse events (irAEs) such as pneumonitis caused by PD‐L1 inhibitors is lower than that of PD‐1 (4.3% vs. 2.1%).12